Elabela‐apelin‐12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1‐P2X7 signaling pathway
Journal of Cellular Biochemistry · 2023-04 · 124 (4) · 586-605
DOI: 10.1002/jcb.30392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2023-03. Verfasst von Zhe Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Key Laboratory of tumor microenvironment responsive drug research, Hengyang Medical School, Institute of Pharmacy and Pharmacology, …. Hauptthemen laut MEDLINE: Peptide Hormones, Thrombosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
The elabela‐apelin/angiotensin domain type 1 receptor‐associated protein (APJ) system is an important regulator in certain thrombosis‐related diseases such as atherosclerosis, myocardial infarction, and cerebral infarction. Our previous reports have revealed that apelin exacerbates atherosclerotic lesions. However, the relationship between the elabela‐apelin/APJ system and platelet aggregation and atherothrombosis is unclear. The results of the present study demonstrate that elabela and other endogenous ligands such as apelin‐12, ‐17, and ‐36 induce platelet aggregation and thrombosis by activating the pannexin1(PANX1)‐P2X7 signaling pathway. Interestingly, the diuretic, spironolactone, a novel PANX1 inhibitor, alleviated elabela‐ and apelin isoforms‐induced platelet aggregation and thrombosis. Significantly, two potential antithrombotic drugs were screened out by targeting APJ receptors, including the anti‐HIV ancillary drug cobicistat and the traditional Chinese medicine monomer Schisandrin A. Both cobicistat and Schisandrin A abolished the effects of elabela and apelin isoforms on platelet aggregation, thrombosis, and cerebral infarction. In addition, cobicistat significantly attenuated thrombosis in a ponatinib‐induced zebrafish trunk model. Overall, the elabela–apelin/APJ axis mediated platelet aggregation and thrombosis via the PANX1‐P2X7 signaling pathway in vitro and in vivo. Blocking the APJ receptor with cobicistat/Schisandrin A or inhibiting PANX1 with spironolactone may provide novel therapeutic strategies against thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Provincial Key Laboratory of tumor microenvironment responsive drug research, Hengyang Medical School, Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New…
- Changde Research Center for Artificial Intelligence and Biomedicine, College of Life and Environmental Sciences, Hunan University of Arts and Science, Changde, Hunan, China.
ORCID-Profile: Haoliang Hu, Linxi Chen
Zitieren
APA
Chen, Z., Luo, X., Liu, M., Jiang, J., Li, Y., Huang, Z., Wang, L., Cao, J., He, L., Huang, S., Hu, H., Li, L., & Chen, L. (2023). Elabela‐apelin‐12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1‐P2X7 signaling pathway. Journal of Cellular Biochemistry, 124(4), 586-605. https://doi.org/10.1002/jcb.30392
Vancouver
Chen Z, Luo X, Liu M, Jiang J, Li Y, Huang Z, et al. Elabela‐apelin‐12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1‐P2X7 signaling pathway. Journal of Cellular Biochemistry. 2023;124(4):586-605. doi:10.1002/jcb.30392
BibTeX
@article{Chen2023,
author = {Chen, Zhe and Luo, Xuling and Liu, Meiqing and Jiang, Jinyong and Li, Yao and Huang, Zhen and Wang, Lingzhi and Cao, Jiangang and He, Lu and Huang, Shifang and Hu, Haoliang and Li, Lanfang and Chen, Linxi},
title = {Elabela‐apelin‐12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1‐P2X7 signaling pathway},
journal = {Journal of Cellular Biochemistry},
year = {2023},
volume = {124},
number = {4},
pages = {586--605},
doi = {10.1002/jcb.30392}
}
EUVIMED